Skip to main content

Advertisement

SpringerLink
Log in

Tyrosine Kinase Inhibitor PTK/ZK Enhances the Antitumor Effects of Interferon-α/5-Fluorouracil Therapy for Hepatocellular Carcinoma Cells

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose

There is no standardized treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus. We previously reported the efficacy of interferon-alpha and 5-fluorouracil combination (IFN/5-FU) therapy for these patients and the potential mechanism via the regulation of vascular endothelial growth factor (VEGF). In this study, we showed the VEGF-related effects of IFN/5-FU therapy using VEGF-receptor (VEGFR) selective inhibitor, PTK787/ZK222584 (PTK/ZK), in HCC cells.

Methods

Using two VEGF secreting and VEGFR expressing human HCC cell lines, PLC/PRF/5 and HuH7, we performed growth inhibitory assays in vitro and in vivo, apoptosis assay, cell cycle analysis, and Western blot analysis for the mechanism, with or without PTK/ZK in IFN/5-FU therapy.

Results

The combination of PTK/ZK and IFN/5-FU significantly inhibited cell growth in vitro and tended to reduce tumor growth in vivo in a HuH7 xenograft model in nude mice—in both cases without affecting VEGF secretion. PTK/ZK enhanced the IFN/5-FU induced apoptosis, based on increased proteins levels of Bax and reduced Bcl-xL and Bcl-2. Cell cycle analysis showed different results between the HCC cell lines following the combination therapy, possibly due to differences in p21 protein.

Conclusions

VEGF signaling inhibition would support an antitumor effect of IFN/5-FU therapy against HCC cell lines via induction of apoptosis and cell cycle delay.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ikai I, Hatano E, Hasegawa S, et al. Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein. J Am Coll Surg. 2006;202:431–8.

    Article  PubMed  Google Scholar 

  2. Le Treut YP, Hardwigsen J, Ananian P, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg. 2006;10:855–62.

    Article  PubMed  Google Scholar 

  3. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol. 2006;12:7561–7.

    CAS  PubMed  Google Scholar 

  4. Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 2002;94:435–42.

    Article  CAS  PubMed  Google Scholar 

  5. Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer. 2005;93:557–64.

    Article  CAS  PubMed  Google Scholar 

  6. Nagano H, Sakon M, Eguchi H, et al. Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology. 2007;54:172–9.

    CAS  PubMed  Google Scholar 

  7. Nagano H, Miyamoto A, Wada H, et al. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer. 2007;110:2493–501.

    Article  CAS  PubMed  Google Scholar 

  8. Wada H, Nagano H, Yamamoto H, et al. Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. BMC Cancer. 2009;9:361.

    Article  PubMed  Google Scholar 

  9. Wada H, Nagano H, Yamamoto H, et al. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncol Rep. 2007;18:801–9.

    CAS  PubMed  Google Scholar 

  10. Ribatti D, Vacca A, Nico B, Sansonno D, Dammacco F. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev. 2006;32:437–44.

    Article  CAS  PubMed  Google Scholar 

  11. Sun HC, Tang ZY. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol. 2004;130:307–19.

    Article  PubMed  Google Scholar 

  12. Moon WS, Rhyu KH, Kang MJ, et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol. 2003;16:552–7.

    Article  PubMed  Google Scholar 

  13. Yoshiji H, Noguchi R, Kuriyama S, et al. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development. Oncol Rep. 2005;13:853–7.

    CAS  PubMed  Google Scholar 

  14. Wada H, Nagano H, Yamamoto H, et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 2006;26:414–23.

    Article  CAS  PubMed  Google Scholar 

  15. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 2009;100:1–8.

    Article  CAS  PubMed  Google Scholar 

  16. Marijon H, Faivre S, Raymond E. Targeted therapies in hepatocellular carcinomas: recent results and future development. Bull Cancer. 2009;96:553–61.

    CAS  PubMed  Google Scholar 

  17. Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2005;65:3691–9.

    Article  CAS  PubMed  Google Scholar 

  18. Eguchi H, Nagano H, Yamamoto H, et al. Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res. 2000;6:2881–90.

    CAS  PubMed  Google Scholar 

  19. Nakamura M, Nagano H, Sakon M, et al. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol. 2007;46:77–88.

    Article  CAS  PubMed  Google Scholar 

  20. Kondo M, Nagano H, Wada H, et al. Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Clin Cancer Res. 2005;11:1277–86.

    Article  CAS  PubMed  Google Scholar 

  21. Yamamoto T, Nagano H, Sakon M, et al. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. Clin Cancer Res. 2004;10:7884–95.

    Article  CAS  PubMed  Google Scholar 

  22. Noda T, Nagano H, Takemasa I, et al. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer. 2009;100:1647–58.

    Article  CAS  PubMed  Google Scholar 

  23. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60:2178–89.

    CAS  PubMed  Google Scholar 

  24. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998;273:30336–43.

    Article  CAS  PubMed  Google Scholar 

  25. Nor JE, Christensen J, Liu J, et al. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res. 2001;61:2183–8.

    CAS  PubMed  Google Scholar 

  26. Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther. 2003;98:129–42.

    Article  CAS  PubMed  Google Scholar 

  27. Hata T, Yamamoto H, Ngan CY, et al. Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells. Mol Cancer Ther. 2005;4:1585–94.

    Article  CAS  PubMed  Google Scholar 

  28. Lee TK, Man K, Poon RT, Lo CM, Ng IO, Fan ST. Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma. Oncol Rep. 2004;12:25–31.

    CAS  PubMed  Google Scholar 

  29. Martin J, Dufour JF. Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol. 2008;14:1720–33.

    Article  CAS  PubMed  Google Scholar 

  30. Qin LF, Ng IO, Fan ST, Ng M. p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer. 1998;79:424–8.

    Article  CAS  PubMed  Google Scholar 

  31. Hsu IC, Tokiwa T, Bennett W, et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis. 1993;14:987–92.

    Article  CAS  PubMed  Google Scholar 

  32. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994;54:3391–5.

    CAS  PubMed  Google Scholar 

  33. Nakaji M, Yano Y, Ninomiya T, et al. IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis. 2004;25:389–97.

    Article  CAS  PubMed  Google Scholar 

  34. Puisieux A, Galvin K, Troalen F, et al. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J. 1993;7:1407–13.

    CAS  PubMed  Google Scholar 

  35. Fan G, Ma X, Wong PY, Rodrigues CM, Steer CJ. p53 dephosphorylation and p21(Cip1/Waf1) translocation correlate with caspase-3 activation in TGF-beta1-induced apoptosis of HuH-7 cells. Apoptosis. 2004;9:211–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan

    Masahiro Murakami MD, Shogo Kobayashi MD, PhD, Shigeru Marubashi MD, PhD, Yoshito Tomimaru MD, Takehiro Noda MD, PhD, Hiroshi Wada MD, PhD, Hidetoshi Eguchi MD, PhD, Yutaka Takeda MD, PhD, Masahiro Tanemura MD, PhD, Koji Umeshita MD, PhD, Yuichiro Doki MD, PhD, Masaki Mori MD, PhD & Hiroaki Nagano MD, PhD

Authors
  1. Masahiro Murakami MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shogo Kobayashi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeru Marubashi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshito Tomimaru MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takehiro Noda MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Wada MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hidetoshi Eguchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yutaka Takeda MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masahiro Tanemura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Koji Umeshita MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yuichiro Doki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Masaki Mori MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hiroaki Nagano MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroaki Nagano MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murakami, M., Kobayashi, S., Marubashi, S. et al. Tyrosine Kinase Inhibitor PTK/ZK Enhances the Antitumor Effects of Interferon-α/5-Fluorouracil Therapy for Hepatocellular Carcinoma Cells. Ann Surg Oncol 18, 589–596 (2011). https://doi.org/10.1245/s10434-010-1310-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1310-y

Keywords

Search

Navigation